1. EXECUTIVE SUMMARY
1.1. Market Snapshot
1.2. Key Findings
1.3. Analyst Insights
1.4. Strategic Recommendations
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Data Collection
2.3. Market Size Estimation
2.4. Forecasting Model
2.5. Assumptions & Limitations
3. MARKET OVERVIEW, SIZE, AND FORECAST
3.1. Market Introduction
3.2. Market Definition & Scope
3.3. Evolution of the Industry
3.4. Key Trends Shaping the Market
3.5. Global Market Size (Historical: 2021–2025)
3.6. Forecast (2026-2031)
3.7. Prevalence Data
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Market Opportunities
4.4. Market Challenges
5. BUSINESS LANDSCAPE
5.1. Industry Value Chain Analysis
5.2. Pricing Analysis
5.3. Reimbursement Scenario
6. TECHNOLOGICAL LANDSCAPE
6.1. Emerging Technologies
6.2. Pipeline Analysis
6.3. AI / Digital Health Integration
7. REGULATORY FRAMEWORK
7.1. FDA / EMA / CDSCO Guidelines
7.2. Approval Processes
7.3. Compliance Requirements
8. MARKET SEGMENTATION (2021-2031)
8.1. By Platform Type
8.1.1. mRNA Platforms
8.1.2. DNA Platforms
8.1.3. Viral Vector Platforms
8.1.4. Protein Subunit Platforms
8.1.5. Nanoparticle Platforms
8.1.6. Others
8.2. By Target Disease
8.2.1. Influenza
8.2.2. Coronavirus
8.2.3. HIV
8.2.4. Cancer Vaccines
8.2.5. Others
8.3. By Stage of Development
8.3.1. Preclinical
8.3.2. Phase I
8.3.3. Phase II
8.3.4. Phase III
8.3.5. Commercialized
8.4. By End-User
8.4.1. Pharmaceutical & Biotechnology Companies
8.4.2. Research Institutes
8.4.3. Government & Defense Organizations
8.4.4. Contract Research Organizations (CROs)
9. GEOGRAPHICAL ANALYSIS (2021-2031)
9.1. North America
9.2. Europe
9.3. Asia-Pacific
9.4. South America
9.5. Middle East & Africa
10. COUNTRY ANALYSIS (2021-2031)
10.1. United States
10.2. Germany
10.3. United Kingdom
10.4. China
10.5. Japan
10.6. India
10.7. South Korea
10.8. Canada
10.9. Australia
10.10. Switzerland
10.11. France
10.12. Singapore
10.13. Israel
10.14. Brazil
11. COMPETITIVE LANDSCAPE
11.1. Market Share Analysis
11.2. Competitive Benchmarking
11.3. Strategic Developments
11.4. Mergers & Acquisitions
11.5. Partnerships
11.6. Product Launches
12. COMPANY PROFILES
12.1. Moderna
12.1.1. Overview
12.1.2. Financials
12.1.3. Product Portfolio
12.1.4. Recent Developments
12.2. Pfizer / BioNTech
12.2.1. Overview
12.2.2. Financials
12.2.3. Product Portfolio
12.2.4. Recent Developments
12.3. CureVac
12.3.1. Overview
12.3.2. Financials
12.3.3. Product Portfolio
12.3.4. Recent Developments
12.4. GSK
12.4.1. Overview
12.4.2. Financials
12.4.3. Product Portfolio
12.4.4. Recent Developments
12.5. Sanofi
12.5.1. Overview
12.5.2. Financials
12.5.3. Product Portfolio
12.5.4. Recent Developments
12.6. AstraZeneca
12.6.1. Overview
12.6.2. Financials
12.6.3. Product Portfolio
12.6.4. Recent Developments
12.7. Novavax
12.7.1. Overview
12.7.2. Financials
12.7.3. Product Portfolio
12.7.4. Recent Developments
12.8. Inovio Pharmaceuticals
12.8.1. Overview
12.8.2. Financials
12.8.3. Product Portfolio
12.8.4. Recent Developments
12.9. VBI Vaccines
12.9.1. Overview
12.9.2. Financials
12.9.3. Product Portfolio
12.9.4. Recent Developments
12.10. Arcturus Therapeutics
12.10.1. Overview
12.10.2. Financials
12.10.3. Product Portfolio
12.10.4. Recent Developments
12.11. Gritstone Bio
12.11.1. Overview
12.11.2. Financials
12.11.3. Product Portfolio
12.11.4. Recent Developments
12.12. GeoVax Labs
12.12.1. Overview
12.12.2. Financials
12.12.3. Product Portfolio
12.12.4. Recent Developments
13. INVESTMENT & FUNDING ANALYSIS
13.1. Venture Capital Trends
13.2. Government Funding
13.3. R&D Investments
14. FUTURE OUTLOOK
14.1. Key Growth Areas
14.2. Disruptive Trends